Blinded; Infliximab, Recombinant


Indications and Reactions:

Role Indications Reactions
Primary
Crohn's Disease 32.9%
Colitis Ulcerative 13.7%
Kawasaki's Disease 10.2%
Premedication 8.6%
Rheumatoid Arthritis 6.1%
Psoriasis 4.8%
Hepatitis C 3.7%
Ankylosing Spondylitis 2.6%
Gastrointestinal Disorder Therapy 2.6%
Osteoporosis 2.4%
Pain 2.4%
Idiopathic Pulmonary Fibrosis 2.1%
Hypertension 1.7%
Anaemia 1.1%
Paternal Drugs Affecting Foetus 1.1%
Pemphigus 0.9%
Anaesthesia 0.8%
Analgesic Therapy 0.8%
Cachexia 0.8%
Headache 0.8%
Tuberculosis 12.0%
Pulmonary Tuberculosis 11.0%
Coronary Artery Dilatation 9.0%
Pyrexia 9.0%
Vomiting 7.0%
Tonsillitis 6.0%
Rash 5.0%
Drug Exposure Before Pregnancy 4.0%
Kawasaki's Disease 4.0%
Neoplasm Malignant 4.0%
Urinary Tract Infection 4.0%
Abdominal Neoplasm 3.0%
Arthritis 3.0%
Cytomegalovirus Infection 3.0%
Eosinophilic Myocarditis 3.0%
Pneumonia Legionella 3.0%
Rash Pruritic 3.0%
Squamous Cell Carcinoma 3.0%
Basal Cell Carcinoma 2.0%
Breast Cancer 2.0%
Secondary
Crohn's Disease 45.0%
Premedication 23.4%
Pain 6.6%
Colitis Ulcerative 3.8%
Anaesthesia 2.6%
Analgesic Therapy 2.6%
Nutritional Supplementation 2.6%
Asthma 2.2%
Cachexia 1.7%
Idiopathic Pulmonary Fibrosis 1.3%
Migraine 1.3%
Sedative Therapy 1.3%
Thrombosis Prophylaxis 0.9%
Rheumatoid Arthritis 0.8%
Vitamin B12 Deficiency 0.7%
Insomnia 0.7%
Vitamin Supplementation 0.7%
Apheresis 0.6%
Hepatitis C 0.6%
Psoriasis 0.6%
Vomiting 12.4%
Diarrhoea 11.2%
Neoplasm Malignant 9.9%
Tonsillitis 8.7%
Basal Cell Carcinoma 7.5%
Pneumonia Legionella 7.5%
Cytomegalovirus Infection 5.6%
Pulmonary Tuberculosis 4.3%
Pyrexia 4.3%
Tuberculosis 4.3%
Lupus-like Syndrome 3.7%
Abdominal Neoplasm 3.1%
Crohn's Disease 2.5%
Drug Exposure Before Pregnancy 2.5%
Rib Fracture 2.5%
Spinal Compression Fracture 2.5%
Arthritis 1.9%
Eosinophilic Myocarditis 1.9%
Intestinal Fistula 1.9%
Nausea 1.9%

Drug Data